SENORES PHARMACEUTICALS L (SENORES) - Total Assets
Based on the latest financial reports, SENORES PHARMACEUTICALS L (SENORES) holds total assets worth Rs12.88 Billion INR (≈ $139.31 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check SENORES cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
SENORES PHARMACEUTICALS L - Total Assets Trend (2022–2025)
This chart illustrates how SENORES PHARMACEUTICALS L's total assets have evolved over time, based on quarterly financial data. Check SENORES PHARMACEUTICALS L cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
SENORES PHARMACEUTICALS L - Asset Composition Analysis
Current Asset Composition (March 2025)
SENORES PHARMACEUTICALS L's total assets of Rs12.88 Billion consist of 4959.8% current assets and -4859.8% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 723.5% |
| Accounts Receivable | Rs2.42 Billion | 1660.6% |
| Inventory | Rs566.30 Million | 388.8% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs1.83 Billion | 1253.6% |
| Goodwill | Rs382.10 Million | 262.3% |
Asset Composition Trend (2022–2025)
This chart illustrates how SENORES PHARMACEUTICALS L's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is SENORES PHARMACEUTICALS L worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SENORES PHARMACEUTICALS L's current assets represent 4959.8% of total assets in 2025, an increase from 45.7% in 2022.
- Cash Position: Cash and equivalents constituted 723.5% of total assets in 2025, up from 3.4% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1515.0% of total assets, an increase from 14.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 1660.6% of total assets.
SENORES PHARMACEUTICALS L Competitors by Total Assets
Key competitors of SENORES PHARMACEUTICALS L based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $207.62 Billion |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
SENORES PHARMACEUTICALS L - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 1.69 | 1.01 |
| Quick Ratio | 2.16 | 1.38 | 0.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs3.86 Billion | Rs1.11 Billion | Rs34.09 Million |
SENORES PHARMACEUTICALS L - Advanced Valuation Insights
This section examines the relationship between SENORES PHARMACEUTICALS L's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.06 |
| Latest Market Cap to Assets Ratio | 4.50 |
| Asset Growth Rate (YoY) | -97.7% |
| Total Assets | Rs145.66 Million |
| Market Capitalization | $655.14 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values SENORES PHARMACEUTICALS L's assets at a significant premium (4.50x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: SENORES PHARMACEUTICALS L's assets decreased by 97.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SENORES PHARMACEUTICALS L (2022–2025)
The table below shows the annual total assets of SENORES PHARMACEUTICALS L from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs145.66 Million ≈ $1.58 Million |
-97.66% |
| 2024-03-31 | Rs6.22 Billion ≈ $67.25 Million |
+374.53% |
| 2023-03-31 | Rs1.31 Billion ≈ $14.17 Million |
+121.55% |
| 2022-03-31 | Rs591.52 Million ≈ $6.40 Million |
-- |
About SENORES PHARMACEUTICALS L
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, ne… Read more